Related Experiment Video

Updated: Feb 21, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

5.0K

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018

Ruben A Mesa, Catriona Jamieson, Ravi Bhatia

    Journal of the National Comprehensive Cancer Network : JNCCN
    |October 7, 2017
    PubMed

    Insights

    Myeloproliferative neoplasms like polycythemia vera and essential thrombocythemia carry risks of blood clots and transformation. New guidelines offer updated strategies for diagnosis and management based on genetic insights.

    Area of Science:

    • Hematology
    • Oncology
    • Genetics

    Background:

    • Myeloproliferative neoplasms (MPNs) encompass myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET).
    • PV and ET present significant risks for thrombohemorrhagic complications and potential progression to MF and acute myeloid leukemia.
    • Advances in understanding MPN pathogenesis, particularly genetic mutations, have refined diagnostic and therapeutic approaches.

    Purpose of the Study:

    • To discuss updated NCCN Guideline recommendations for managing PV and ET.
    • To highlight advancements in risk stratification and treatment strategies for PV and ET.
    • To provide insights into special considerations for PV and ET patient care.

    Main Methods:

    • Review of the latest NCCN Guidelines for PV and ET.
    • Analysis of diagnostic criteria and risk stratification models.
    • Evaluation of current treatment options and emerging therapies.

    Main Results:

    • Identification of key mutations driving PV and ET pathogenesis.
    • Refined risk stratification enabling personalized treatment selection.
    • Updated therapeutic recommendations incorporating targeted agents and improved monitoring.

    Conclusions:

    • The diagnosis and management of PV and ET have significantly evolved due to genetic discoveries.
    • Adherence to updated NCCN Guidelines is crucial for optimizing patient outcomes.
    • Ongoing research continues to refine MPN management strategies.

    More Related Videos

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

    Published on: November 3, 2018

    12.4K
    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

    Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

    Published on: March 5, 2018

    30.7K

    Related Concept Videos

    Differentiation of Common Myeloid Progenitor Cells01:15

    Differentiation of Common Myeloid Progenitor Cells

    Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
    4.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    5.3K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Bone Marrow Sampling and Transplants01:22

    Bone Marrow Sampling and Transplants

    Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
    The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
    1.7K